Contraindicated (1)bortezomib will raise the stage or effect of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may possibly maximize mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. Other consequences, for instance a pores and skin rash, may not be significant but https://shanetzgl29630.blogsuperapp.com/27249616/the-single-best-strategy-to-use-for-lp-pla2-in-1